Success Metrics

Clinical Success Rate

80.6%

Based on 50 completed trials

Completion Rate

81%(50/62)

Active Trials

3(4%)

Results Posted

54%(27 trials)

Terminated

12(14%)

Phase Distribution

Ph phase_2

16%

Ph phase_3

22%

Ph not_applicable

11%

Ph phase_4

20%

Ph early_phase_1

Ph phase_1

22%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution80 total trials

Early Phase 1First-in-human

5(6.3%)

Phase 1Safety & dosage

18(22.5%)

Phase 2Efficacy & side effects

13(16.3%)

Phase 3Large-scale testing

18(22.5%)

Phase 4Post-market surveillance

17(21.3%)

N/ANon-phased studies

9(11.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

75.8%

50 of 66 finished

Non-Completion Rate

24.2%

16 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(6)

Completed(50)

Terminated(16)

Other(11)

Detailed Status

Completed50

Terminated12

unknown11

Withdrawn4

Not yet recruiting3

Active, not recruiting2

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

80.6%

Most Advanced

Phase 4

Trials by Phase

Early Phase 15 (6.3%)

Phase 118 (22.5%)

Phase 213 (16.3%)

Phase 318 (22.5%)

Phase 417 (21.3%)

N/A9 (11.3%)

Trials by Status

not_yet_recruiting34%

recruiting11%

unknown1113%

withdrawn45%

active_not_recruiting22%

completed5060%

terminated1214%

Recent Activity

3 active trials

Showing 5 of 83

not_yet_recruitingearly_phase_1

Clinical Trials (83)

Showing 20 of 83 trialsScroll for more

NCT07218653Early Phase 1

Human Cerebrovascular Blood Flow and Sex Differences in Metabolic Syndrome

Not Yet Recruiting

NCT07173179Phase 4

Papillary Epinephrine Injection vs Rectal Indomethacin

Completed

NCT07661498Phase 4

Indomethacin for Biliary ERCP Patients

Not Yet Recruiting

NCT01719926Phase 1

Phase I Platinum Based Chemotherapy Plus Indomethacin

Completed

NCT05538247Early Phase 1

Saccharomyces Boulardii CNCM I-745 on Intestinal Barrier Function

Completed

NCT02205762Phase 2

LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis

Active Not Recruiting

NCT02858310Phase 1

E7 TCR T Cells for Human Papillomavirus-Associated Cancers

Completed

NCT02950259Phase 1

Pre-operative IRX-2 in Early Stage Breast Cancer (ESBC)

Completed

NCT05035407Phase 1

T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung and Other KK-LC-1 Positive Epithelial Cancers

Terminated

NCT00262470Phase 1

Treatment of Orthostatic Intolerance

Active Not Recruiting

NCT06572917Phase 2

Single-dose Prophylactic INdomethacin in Extremely Preterm Infants

Not Yet Recruiting

NCT06253702Phase 4

Brain Blood Flow Responses to Stress: Sex Differences

Completed

NCT03267680Phase 2

IRX-2 Regimen in Treating Women With Cervical Squamous Intraepithelial Neoplasia 3 or Squamous Vulvar Intraepithelial Neoplasia 3

Terminated

NCT03713879Phase 3

Comparative Effectiveness Between Indomethacin and Pancreatic Stenting in the Prevention of Post ERCP Pancreatitis

Recruiting

NCT03648437Phase 1

Paracetamol And Ibuprofen/Indomethacin in Closing Patent Ductus Arteriosus

Terminated

NCT04207060Phase 1

Trial of Indomethacin in Chronic Pancreatitis

Completed

NCT04347720

Canadian National PDA Treatment Study

Completed

NCT02609386Phase 2

IRX-2 Regimen in Patients With Newly Diagnosed Stage II, III, or IVA Squamous Cell Carcinoma of the Oral Cavity

Completed

NCT05999708Phase 1

A First Time in Human Study to Evaluate the Safety and Tolerability of GSK4381406 in Healthy Participants

Withdrawn

NCT02935205Phase 1

Enzalutamide and Indomethacin in Treating Patients With Recurrent or Metastatic Hormone-Resistant Prostate Cancer

Unknown

Drug Details

Intervention Type: DRUG
Total Trials: 83